In the News Date Title April 1, 2021 SUBSPECIALTY NEWS: Ophthalmic bevacizumab, add-on AMD therapy, gene therapy, and more February 10, 2021 With New Clarity of Trial Data, Outlook Therapeutics Stock Rebounds January 5, 2021 The Outlook on Getting Regulatory-Approved Bevacizumab to Market December 9, 2020 Targeting Retinal Diseases with an Ophthalmic Formulation of Bevacizumab October 6, 2020 Spotlight Q&A: Outlook Therapeutics - Developing First Ophthalmic Formulation of Bevacizumab for FDA Approval January 7, 2019 Proactive Investors interview with Outlook Therapeutics CEO Larry Kenyon
